Metabolic Disorders Therapeutics Market Report

Global and Region Metabolic Disorders Therapeutics Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：184
  • REPORT CODE：GMM892206
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Metabolic Disorders Therapeutics market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Metabolic Disorders Therapeuticsmarket, defines the market attractiveness level of Metabolic Disorders Therapeutics market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Metabolic Disorders Therapeutics industry, describes the types of Metabolic Disorders Therapeutics market, the applications of major players and the market size, and deeply analyzes the current situation of the global Metabolic Disorders Therapeutics market and the development prospects and opportunities of Metabolic Disorders Therapeutics industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Metabolic Disorders Therapeutics market in Chapter 13.

    By Player:

    • Boehringer Ingelheim

    • AstraZeneca

    • Sanofi

    • Merck

    • Novo Nordisk

    • CymaBay Therapeutics

    • AbbVie

    • Biocon

    • Actelion Pharmaceuticals

    • Eli Lilly and Company

    By Type:

    • Metachromatic Leukodystrophy

    • Globoid Leukodystrophy

    • Hepatic Encephalopathy

    • Others

    By End-User:

    • Diabetes

    • Obesity

    • Hypercholesterolemia

    • Lysosomal Storage Diseases

    • Others

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Metabolic Disorders Therapeutics Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Metabolic Disorders Therapeutics Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Metabolic Disorders Therapeutics Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Metabolic Disorders Therapeutics Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Metabolic Disorders Therapeutics Market Analysis and Outlook to 2022

    • 7.1 Global Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.2 United States Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.3 Europe Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.4 China Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.5 Japan Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.6 India Metabolic Disorders Therapeutics Consumption (2017-2022)

    • 7.7 South Korea Metabolic Disorders Therapeutics Consumption (2017-2022)

    8 Region and Country-wise Metabolic Disorders Therapeutics Market Analysis and Outlook to 2028

    • 8.1 Global Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.2 United States Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.3 Europe Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.4 China Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.5 Japan Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.6 India Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    • 8.7 South Korea Metabolic Disorders Therapeutics Consumption Forecast (2022-2028)

    9 Global Metabolic Disorders Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Metabolic Disorders Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Metachromatic Leukodystrophy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Globoid Leukodystrophy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Hepatic Encephalopathy Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Metabolic Disorders Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Diabetes Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Obesity Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Hypercholesterolemia Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Lysosomal Storage Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Others Consumption and Growth Rate (2017-2022)

    10 Global Metabolic Disorders Therapeutics Market Outlook by Types and Applications to 2028

    • 10.1 Global Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Metachromatic Leukodystrophy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Globoid Leukodystrophy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Hepatic Encephalopathy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Diabetes Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Obesity Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Hypercholesterolemia Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global Lysosomal Storage Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    11 Global Metabolic Disorders Therapeutics Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Metabolic Disorders Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Metabolic Disorders Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Metabolic Disorders Therapeutics Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Metabolic Disorders Therapeutics Market Competitive Analysis

    • 14.1 Boehringer Ingelheim

      • 14.1.1 Boehringer Ingelheim Company Details

      • 14.1.2 Boehringer Ingelheim Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Product and Service

    • 14.2 AstraZeneca

      • 14.2.1 AstraZeneca Company Details

      • 14.2.2 AstraZeneca Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 AstraZeneca Metabolic Disorders Therapeutics Product and Service

    • 14.3 Sanofi

      • 14.3.1 Sanofi Company Details

      • 14.3.2 Sanofi Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Sanofi Metabolic Disorders Therapeutics Product and Service

    • 14.4 Merck

      • 14.4.1 Merck Company Details

      • 14.4.2 Merck Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Merck Metabolic Disorders Therapeutics Product and Service

    • 14.5 Novo Nordisk

      • 14.5.1 Novo Nordisk Company Details

      • 14.5.2 Novo Nordisk Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Novo Nordisk Metabolic Disorders Therapeutics Product and Service

    • 14.6 CymaBay Therapeutics

      • 14.6.1 CymaBay Therapeutics Company Details

      • 14.6.2 CymaBay Therapeutics Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Product and Service

    • 14.7 AbbVie

      • 14.7.1 AbbVie Company Details

      • 14.7.2 AbbVie Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 AbbVie Metabolic Disorders Therapeutics Product and Service

    • 14.8 Biocon

      • 14.8.1 Biocon Company Details

      • 14.8.2 Biocon Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Biocon Metabolic Disorders Therapeutics Product and Service

    • 14.9 Actelion Pharmaceuticals

      • 14.9.1 Actelion Pharmaceuticals Company Details

      • 14.9.2 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product and Service

    • 14.10 Eli Lilly and Company

      • 14.10.1 Eli Lilly and Company Company Details

      • 14.10.2 Eli Lilly and Company Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Metabolic Disorders Therapeutics

    • Figure Metabolic Disorders Therapeutics Picture

    • Table Global Metabolic Disorders Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Metabolic Disorders Therapeutics Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Metabolic Disorders Therapeutics Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Metabolic Disorders Therapeutics Consumption by Country (2017-2022)

    • Figure United States Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure China Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Metabolic Disorders Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Global Metabolic Disorders Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Metabolic Disorders Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Metachromatic Leukodystrophy Consumption and Growth Rate (2017-2022)

    • Figure Global Globoid Leukodystrophy Consumption and Growth Rate (2017-2022)

    • Figure Global Hepatic Encephalopathy Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Diabetes Consumption and Growth Rate (2017-2022)

    • Figure Global Obesity Consumption and Growth Rate (2017-2022)

    • Figure Global Hypercholesterolemia Consumption and Growth Rate (2017-2022)

    • Figure Global Lysosomal Storage Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Metachromatic Leukodystrophy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Globoid Leukodystrophy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hepatic Encephalopathy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Diabetes Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Obesity Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hypercholesterolemia Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Lysosomal Storage Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Metabolic Disorders Therapeutics Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Metabolic Disorders Therapeutics Export by Region (Top 5 Countries) (2017-2028)

    • Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Metabolic Disorders Therapeutics Product and Service

    • Table AstraZeneca (Foundation Year, Company Profile and etc.)

    • Table AstraZeneca Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Metabolic Disorders Therapeutics Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Metabolic Disorders Therapeutics Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Metabolic Disorders Therapeutics Product and Service

    • Table Novo Nordisk (Foundation Year, Company Profile and etc.)

    • Table Novo Nordisk Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Metabolic Disorders Therapeutics Product and Service

    • Table CymaBay Therapeutics (Foundation Year, Company Profile and etc.)

    • Table CymaBay Therapeutics Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table CymaBay Therapeutics Metabolic Disorders Therapeutics Product and Service

    • Table AbbVie (Foundation Year, Company Profile and etc.)

    • Table AbbVie Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Metabolic Disorders Therapeutics Product and Service

    • Table Biocon (Foundation Year, Company Profile and etc.)

    • Table Biocon Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Metabolic Disorders Therapeutics Product and Service

    • Table Actelion Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Actelion Pharmaceuticals Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product and Service

    • Table Eli Lilly and Company (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly and Company Metabolic Disorders Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly and Company Metabolic Disorders Therapeutics Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US